Loading...
Market
Story
FDA Approves Pfizer's Once-Weekly HYMPAVZI for Hemophilia Treatment
Oct 11, 2024, 05:39 PM
The U.S. Food and Drug Administration (FDA) has approved Pfizer's HYMPAVZI™ (marstacimab-hncq) for the treatment of adults and adolescents with Hemophilia A or B without inhibitors. This approval marks the first once-weekly injection available for the two main types of this rare bleeding disorder. Hemophilia is a potentially deadly genetic condition that prevents blood from clotting properly. Pfizer's stock symbol is $PFE.
View original story
Similar markets
Yes • 50%
No • 50%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
No new competitors • 25%
1-2 new competitors • 25%
3-4 new competitors • 25%
5+ new competitors • 25%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Travere Therapeutics • 25%
Novartis • 25%
Calliditas • 25%
Other • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Ascendis Pharma • 25%
Takeda • 25%
Another existing company • 25%
A new entrant • 25%
BEAM-101 leads • 33%
Reni-cel leads • 33%
Casgevy leads • 33%
Purdue Pharma • 25%
ARS Pharmaceuticals • 25%
Pfizer • 25%
Other • 25%
Amjevita • 25%
Wezlana • 25%
Other • 25%
None • 25%
Roche's CT-996 has the largest market share • 25%
Novo Nordisk has the largest market share • 25%
Eli Lilly has the largest market share • 25%
Other companies have the largest market share • 25%